Schedule III Substance

Known as: C-III, CIII, SPL DEA Schedule III 
A category of drugs that have less potential for abuse or addiction than Schedule I or II drugs and have a useful medical purpose.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
  • Jaak Jaeken
  • Annals of the New York Academy of Sciences
  • 2010
Congenital (genetic) disorders of glycosylation (CDG) are a rapidly growing disease family, with some 45 members reported since… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Extended multilocus sequence typing (MLST) analysis of atypical Escherichia isolates was used to identify five novel phylogenetic… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND Activation of vascular endothelial cells (ECs) plays an important role in atherogenesis and plaque instability… (More)
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2003
Highly Cited
2003
OBJECTIVE Triglyceride-rich lipoproteins that contain apolipoprotein CIII (apoCIII) are prominent in diabetic dyslipidemia. We… (More)
  • table 2
  • table 3
Is this relevant?
Highly Cited
2000
Highly Cited
2000
BACKGROUND Plasma triglyceride concentration has been an inconsistent independent risk factor for coronary heart disease, perhaps… (More)
  • table 1
  • table 2
  • table 3
  • table 3
  • figure 1
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Fluctuations in rates of gene expression can produce highly erratic time patterns of protein production in individual cells and… (More)
  • figure 1
  • figure 2
  • table 2
  • table 3
  • figure 5
Is this relevant?
Highly Cited
1995
Highly Cited
1995
Overexpression of plasma apolipoprotein CIII (apo CIII) causes hypertriglyceridemia in transgenic mice. A genetically variant… (More)
Is this relevant?
Highly Cited
1992
Highly Cited
1992
Hypertriglyceridemia is common in the general population, but its mechanism is largely unknown. In previous work human apo CIII… (More)
  • table I
  • figure 1
  • figure 2
  • table III
  • figure 3
Is this relevant?
Highly Cited
1986
Highly Cited
1986
Previous data suggest that apolipoprotein (apo) CIII may inhibit both triglyceride hydrolysis by lipoprotein lipase (LPL) and apo… (More)
  • table I
  • figure 1
  • table II
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
1985
Highly Cited
1985
The genes for two of the proteins of the plasma lipid transport system, apolipoprotein AI (apoAI) and CIII (apoCIII) are closely… (More)
  • figure 1
  • figure 2
  • figure 5
  • figure 6
Is this relevant?